AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
ephedrine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| sympathomimetics | 1024 | 299-42-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 50 | mg | P |
| 8 | mg | N |
| 50 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| S (Water solubility) | 56.18 mg/mL | Bocci G, Oprea TI, Benet LZ |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK3,MAP3K21,MAP3K7,MAPK7,NTRK2,PDK2,PDK4,PIM2,PRKDC,SIK2,SIK3,SYK,TEK,TGFBR1,ZAP70 | 33 | |||
| kinase-selectivity-class | AXL,EIF2AK3,GRK2,PDK4 | 4 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Bradycardia | 135.43 | 33.72 | 59 | 2425 | 83788 | 90542175 |
| Maternal exposure during delivery | 128.56 | 33.72 | 28 | 2456 | 3818 | 90622145 |
| Hypotension | 125.97 | 33.72 | 89 | 2395 | 325308 | 90300655 |
| Anaphylactic shock | 122.21 | 33.72 | 42 | 2442 | 31575 | 90594388 |
| Anterior spinal artery syndrome | 119.82 | 33.72 | 17 | 2467 | 182 | 90625781 |
| Spinal cord injury | 90.64 | 33.72 | 17 | 2467 | 1092 | 90624871 |
| Rhythm idioventricular | 86.22 | 33.72 | 14 | 2470 | 385 | 90625578 |
| Exposure during pregnancy | 84.66 | 33.72 | 62 | 2422 | 238348 | 90387615 |
| Cardiac arrest | 68.45 | 33.72 | 40 | 2444 | 104895 | 90521068 |
| Ventricular tachycardia | 66.01 | 33.72 | 25 | 2459 | 24683 | 90601280 |
| Stress cardiomyopathy | 64.49 | 33.72 | 21 | 2463 | 13334 | 90612629 |
| Cardio-respiratory arrest | 60.36 | 33.72 | 31 | 2453 | 63109 | 90562854 |
| Anaphylactic reaction | 58.75 | 33.72 | 34 | 2450 | 87490 | 90538473 |
| Mental status changes postoperative | 57.74 | 33.72 | 9 | 2475 | 189 | 90625774 |
| Confusion postoperative | 55.61 | 33.72 | 9 | 2475 | 242 | 90625721 |
| Maternal exposure during pregnancy | 53.28 | 33.72 | 57 | 2427 | 360006 | 90265957 |
| Chorea | 52.11 | 33.72 | 12 | 2472 | 2098 | 90623865 |
| Fanconi syndrome | 47.71 | 33.72 | 11 | 2473 | 1932 | 90624031 |
| Drug reaction with eosinophilia and systemic symptoms | 46.74 | 33.72 | 23 | 2461 | 42735 | 90583228 |
| Congenital clavicular agenesis | 40.40 | 33.72 | 6 | 2478 | 90 | 90625873 |
| Rash maculo-papular | 38.81 | 33.72 | 20 | 2464 | 40913 | 90585050 |
| Eosinophilia | 36.18 | 33.72 | 17 | 2467 | 28516 | 90597447 |
| Paralysis | 35.73 | 33.72 | 13 | 2471 | 11465 | 90614498 |
| Neuralgia | 34.58 | 33.72 | 17 | 2467 | 31483 | 90594480 |
| Tachycardia | 34.55 | 33.72 | 31 | 2453 | 157642 | 90468321 |
| Ischaemic stroke | 33.75 | 33.72 | 15 | 2469 | 22151 | 90603812 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic shock | 138.76 | 31.80 | 48 | 1790 | 23469 | 42596028 |
| Toxicity to various agents | 70.09 | 31.80 | 66 | 1772 | 229070 | 42390427 |
| Anaphylactic reaction | 55.75 | 31.80 | 30 | 1808 | 42713 | 42576784 |
| Administration related reaction | 54.48 | 31.80 | 9 | 1829 | 172 | 42619325 |
| Hyperthermia malignant | 48.66 | 31.80 | 13 | 1825 | 2645 | 42616852 |
| Cardiac arrest | 44.23 | 31.80 | 37 | 1801 | 109283 | 42510214 |
| Hypertonia neonatal | 43.57 | 31.80 | 9 | 1829 | 601 | 42618896 |
| Drug abuse | 43.51 | 31.80 | 36 | 1802 | 104735 | 42514762 |
| Locked-in syndrome | 41.01 | 31.80 | 8 | 1830 | 399 | 42619098 |
| Hypotension | 36.74 | 31.80 | 50 | 1788 | 257581 | 42361916 |
| Embolic stroke | 36.39 | 31.80 | 12 | 1826 | 5028 | 42614469 |
| Tachycardia | 36.36 | 31.80 | 32 | 1806 | 101055 | 42518442 |
| Agitation neonatal | 35.95 | 31.80 | 9 | 1829 | 1419 | 42618078 |
| Eosinophilia | 34.43 | 31.80 | 20 | 1818 | 32879 | 42586618 |
| Haemodynamic instability | 32.13 | 31.80 | 14 | 1824 | 12543 | 42606954 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anaphylactic shock | 255.05 | 26.06 | 90 | 4223 | 51456 | 110533530 |
| Maternal exposure during delivery | 120.78 | 26.06 | 28 | 4285 | 3537 | 110581449 |
| Hypotension | 115.85 | 26.06 | 121 | 4192 | 523728 | 110061258 |
| Anterior spinal artery syndrome | 111.94 | 26.06 | 17 | 4296 | 205 | 110584781 |
| Anaphylactic reaction | 106.06 | 26.06 | 62 | 4251 | 114238 | 110470748 |
| Cardiac arrest | 88.46 | 26.06 | 68 | 4245 | 196685 | 110388301 |
| Toxicity to various agents | 83.59 | 26.06 | 98 | 4215 | 480457 | 110104529 |
| Drug abuse | 81.23 | 26.06 | 62 | 4251 | 177349 | 110407637 |
| Spinal cord injury | 77.75 | 26.06 | 17 | 4296 | 1648 | 110583338 |
| Bradycardia | 77.08 | 26.06 | 57 | 4256 | 155460 | 110429526 |
| Ventricular tachycardia | 73.98 | 26.06 | 37 | 4276 | 49972 | 110535014 |
| Rhythm idioventricular | 71.81 | 26.06 | 14 | 4299 | 771 | 110584215 |
| Eosinophilia | 68.84 | 26.06 | 37 | 4276 | 57899 | 110527087 |
| Stress cardiomyopathy | 68.25 | 26.06 | 25 | 4288 | 15781 | 110569205 |
| Tachycardia | 60.23 | 26.06 | 58 | 4255 | 226587 | 110358399 |
| Metal poisoning | 59.45 | 26.06 | 9 | 4304 | 106 | 110584880 |
| Cardio-respiratory arrest | 58.58 | 26.06 | 43 | 4270 | 115793 | 110469193 |
| Rash maculo-papular | 50.31 | 26.06 | 33 | 4280 | 74189 | 110510797 |
| Haemodynamic instability | 49.45 | 26.06 | 22 | 4291 | 22866 | 110562120 |
| Mental status changes postoperative | 47.13 | 26.06 | 8 | 4305 | 201 | 110584785 |
| Maternal exposure during pregnancy | 45.86 | 26.06 | 53 | 4260 | 254830 | 110330156 |
| Arteriospasm coronary | 45.32 | 26.06 | 16 | 4297 | 9084 | 110575902 |
| Administration related reaction | 43.85 | 26.06 | 8 | 4305 | 307 | 110584679 |
| Chorea | 42.80 | 26.06 | 12 | 4301 | 3223 | 110581763 |
| Confusion postoperative | 42.61 | 26.06 | 8 | 4305 | 360 | 110584626 |
| Angle closure glaucoma | 41.87 | 26.06 | 12 | 4301 | 3487 | 110581499 |
| Procedural hypotension | 41.07 | 26.06 | 11 | 4302 | 2494 | 110582492 |
| Exposure during pregnancy | 40.99 | 26.06 | 41 | 4272 | 167383 | 110417603 |
| Drug reaction with eosinophilia and systemic symptoms | 40.41 | 26.06 | 30 | 4283 | 82065 | 110502921 |
| Airway complication of anaesthesia | 37.66 | 26.06 | 8 | 4305 | 676 | 110584310 |
| Fanconi syndrome | 37.37 | 26.06 | 11 | 4302 | 3508 | 110581478 |
| Circulatory collapse | 36.36 | 26.06 | 22 | 4291 | 42971 | 110542015 |
| Blood pressure decreased | 35.43 | 26.06 | 32 | 4281 | 115059 | 110469927 |
| Locked-in syndrome | 35.03 | 26.06 | 8 | 4305 | 944 | 110584042 |
| Embolic stroke | 31.09 | 26.06 | 12 | 4301 | 8731 | 110576255 |
| Paralysis | 30.53 | 26.06 | 14 | 4299 | 15586 | 110569400 |
| Language disorder | 28.03 | 26.06 | 9 | 4304 | 3829 | 110581157 |
| Hyperthermia malignant | 27.89 | 26.06 | 9 | 4304 | 3891 | 110581095 |
| Ventricular fibrillation | 27.08 | 26.06 | 18 | 4295 | 41295 | 110543691 |
| Bronchospasm | 26.93 | 26.06 | 16 | 4297 | 30223 | 110554763 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A08AA56 | ALIMENTARY TRACT AND METABOLISM ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS Centrally acting antiobesity products |
| ATC | C01CA26 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES Adrenergic and dopaminergic agents |
| ATC | R01AA03 | RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Sympathomimetics, plain |
| ATC | R01AB05 | RESPIRATORY SYSTEM NASAL PREPARATIONS DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE Sympathomimetics, combinations excl. corticosteroids |
| ATC | R03CA02 | RESPIRATORY SYSTEM DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES ADRENERGICS FOR SYSTEMIC USE Alpha- and beta-adrenoreceptor agonists |
| ATC | S01FB02 | SENSORY ORGANS OPHTHALMOLOGICALS MYDRIATICS AND CYCLOPLEGICS Sympathomimetics excl. antiglaucoma preparations |
| FDA MoA | N0000000209 | Adrenergic alpha-Agonists |
| FDA MoA | N0000000245 | Adrenergic beta-Agonists |
| FDA PE | N0000009456 | Increased Norepinephrine Activity |
| FDA EPC | N0000175552 | alpha-Adrenergic Agonist |
| FDA EPC | N0000175555 | beta-Adrenergic Agonist |
| MeSH PA | D000697 | Central Nervous System Stimulants |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D013566 | Sympathomimetics |
| MeSH PA | D014662 | Vasoconstrictor Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018663 | Adrenergic Agents |
| CHEBI has role | CHEBI:65023 | anti-asthmatic agent |
| CHEBI has role | CHEBI:77715 | nasal decongestant |
| FDA EPC | N0000192563 | Norepinephrine Releasing Agent |
Related Drugs by ATC class:
A08AA Centrally acting antiobesity products 15 drugs
C01CA Adrenergic and dopaminergic agents 25 drugs
R01AA Sympathomimetics, plain 13 drugs
R01AB Sympathomimetics, combinations excl. corticosteroids 6 drugs
S01FB Sympathomimetics excl. antiglaucoma preparations 3 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Bronchospasm | indication | 4386001 | |
| Sinus headache | indication | 4969004 | |
| Vasomotor rhinitis | indication | 8229003 | DOID:4730 |
| Bronchitis | indication | 32398004 | DOID:6132 |
| Allergic rhinitis | indication | 61582004 | |
| Nasal discharge | indication | 64531003 | |
| Nasal congestion | indication | 68235000 | |
| Rhinitis | indication | 70076002 | DOID:4483 |
| Sneezing | indication | 76067001 | |
| Common cold | indication | 82272006 | DOID:10459 |
| Headache disorder | indication | 230461009 | |
| Influenza-like symptoms | indication | 315642008 | |
| Seasonal allergic rhinitis | indication | 367498001 | |
| Allergic conjunctivitis | indication | 473460002 | DOID:11204 |
| Intracranial hemorrhage | contraindication | 1386000 | |
| Brain damage | contraindication | 2470005 | |
| Goiter | contraindication | 3716002 | DOID:12176 |
| Ocular hypertension | contraindication | 4210003 | DOID:9282 |
| Gastritis | contraindication | 4556007 | DOID:4029 |
| Tachyarrhythmia | contraindication | 6285003 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Dependent drug abuse | contraindication | 6525002 | |
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Alcoholism | contraindication | 7200002 | |
| Alcohol withdrawal delirium | contraindication | 8635005 | |
| Hyperammonemia | contraindication | 9360008 | |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Chronic obstructive lung disease | contraindication | 13645005 | DOID:3083 |
| Asthenia | contraindication | 13791008 | |
| Hepatic encephalopathy | contraindication | 13920009 | DOID:13413 |
| Hyperkalemia | contraindication | 14140009 | |
| Severe chronic ulcerative colitis | contraindication | 14311001 | |
| Constipation | contraindication | 14760008 | DOID:2089 |
| Disorder of autonomic nervous system | contraindication | 15241006 | |
| Chronic disease of respiratory system | contraindication | 17097001 | |
| Mood swings | contraindication | 18963009 | |
| Pulmonary edema | contraindication | 19242006 | DOID:11396 |
| Hashimoto thyroiditis | contraindication | 21983002 | |
| Myocardial infarction | contraindication | 22298006 | DOID:5844 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Inflammatory bowel disease | contraindication | 24526004 | DOID:0050589 |
| Ventricular tachycardia | contraindication | 25569003 | |
| Acute tuberculosis | contraindication | 25629007 | |
| Alcohol intoxication | contraindication | 25702006 | |
| Shock | contraindication | 27942005 | |
| Toxic megacolon | contraindication | 28536002 | DOID:1770 |
| Atony of colon | contraindication | 29479008 | |
| Hypercapnia | contraindication | 29596007 | |
| Dehydration | contraindication | 34095006 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Depressive disorder | contraindication | 35489007 | |
| Acute hepatitis | contraindication | 37871000 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Hypovolemic shock | contraindication | 39419009 | |
| Disorder of gallbladder | contraindication | 39621005 | DOID:0060262 |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Hypothyroidism | contraindication | 40930008 | DOID:1459 |
| Complete trisomy 21 syndrome | contraindication | 41040004 | DOID:14250 |
| Third trimester pregnancy | contraindication | 41587001 | |
| Body fluid retention | contraindication | 43498006 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Low blood pressure | contraindication | 45007003 | |
| Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
| Pregnancy-induced hypertension | contraindication | 48194001 | |
| Chronic heart failure | contraindication | 48447003 | |
| Bradycardia | contraindication | 48867003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Acidosis | contraindication | 51387008 | |
| Gastrointestinal perforation | contraindication | 51875005 | |
| Coronary arteriosclerosis | contraindication | 53741008 | DOID:3393 |
| Paralytic ileus | contraindication | 55525008 | DOID:8442 |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Peptic reflux disease | contraindication | 57643001 | |
| Multiple organ failure | contraindication | 57653000 | |
| Acute nephropathy | contraindication | 58574008 | |
| Metabolic acidosis | contraindication | 59455009 | |
| Hepatic failure | contraindication | 59927004 | |
| Ulcerative colitis | contraindication | 64766004 | DOID:8577 |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Poisoning by phenobarbital | contraindication | 64921004 | |
| Arterial thrombosis | contraindication | 65198009 | |
| Drug AND/OR toxin-induced diarrhea | contraindication | 65979008 | |
| Substance abuse | contraindication | 66214007 | |
| Benign intracranial hypertension | contraindication | 68267002 | DOID:11459 |
| Psychotic disorder | contraindication | 69322001 | |
| Poisoning by acetaminophen | contraindication | 70273001 | |
| Abnormal vasomotor function | contraindication | 70670009 | |
| Arteriosclerotic vascular disease | contraindication | 72092001 | |
| Hepatic coma | contraindication | 72836002 | DOID:12550 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Sleep apnea | contraindication | 73430006 | DOID:0050847 |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Urethral stricture | contraindication | 76618002 | |
| Spastic paralysis | contraindication | 78403003 | |
| Disturbance of salivary secretion | contraindication | 78948009 | |
| Decreased respiratory function | contraindication | 80954004 | |
| Injury of head | contraindication | 82271004 | |
| Chronic idiopathic constipation | contraindication | 82934008 | |
| Oliguria | contraindication | 83128009 | |
| Cor pulmonale | contraindication | 83291003 | DOID:8515 |
| Hiatal hernia | contraindication | 84089009 | DOID:12642 |
| Open-angle glaucoma | contraindication | 84494001 | DOID:1067 |
| Epilepsy | contraindication | 84757009 | DOID:1826 |
| Pulmonary emphysema | contraindication | 87433001 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Thyrotoxicosis | contraindication | 90739004 | DOID:7997 |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Dermatitis herpetiformis | contraindication | 111196000 | DOID:8505 |
| Acute abdominal pain | contraindication | 116290004 | |
| Procedure on urinary system | contraindication | 118677009 | |
| Gastrointestinal obstruction | contraindication | 126765001 | |
| Neoplasm of brain | contraindication | 126952004 | DOID:1319 |
| Seizure disorder | contraindication | 128613002 | |
| Autonomic dysreflexia | contraindication | 129618003 | |
| Bleeding | contraindication | 131148009 | |
| Liver function tests abnormal | contraindication | 166603001 | |
| Cystic fibrosis | contraindication | 190905008 | DOID:1485 |
| Drug-induced psychosis | contraindication | 191483003 | DOID:1742 |
| Angina pectoris | contraindication | 194828000 | |
| Partial atrioventricular block | contraindication | 195039008 | |
| Acute pancreatitis | contraindication | 197456007 | DOID:2913 |
| Impaired renal function disorder | contraindication | 197663003 | |
| Cerebrovascular accident | contraindication | 230690007 | |
| Coronary artery bypass graft | contraindication | 232717009 | |
| Myocardial dysfunction | contraindication | 233928007 | |
| Gastroesophageal reflux disease | contraindication | 235595009 | DOID:8534 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Hyporeninemic hypoaldosteronism | contraindication | 236464008 | |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Morbid obesity | contraindication | 238136002 | DOID:11981 |
| Sepsis syndrome | contraindication | 238150007 | |
| Hypocomplementemic urticarial vasculitis | contraindication | 239945009 | |
| Rhabdomyolysis | contraindication | 240131006 | |
| Pyloric obstruction | contraindication | 244815007 | |
| Esophageal dysmotility | contraindication | 266434009 | DOID:9192 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Dyspnea | contraindication | 267036007 | |
| Edema | contraindication | 267038008 | |
| Retention of urine | contraindication | 267064002 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Continuous fever | contraindication | 271751000 | |
| Drowsy | contraindication | 271782001 | |
| Exacerbation of asthma | contraindication | 281239006 | |
| Pregnancy, function | contraindication | 289908002 | |
| Lesion of brain | contraindication | 301766008 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
| Neutropenic disorder | contraindication | 303011007 | DOID:1227 |
| Thromboembolic disorder | contraindication | 371039008 | |
| Coma | contraindication | 371632003 | |
| Primary adrenocortical insufficiency | contraindication | 373662000 | |
| Smoking cessation assistance | contraindication | 384742004 | |
| Operation on gastrointestinal tract | contraindication | 386621005 | |
| Hypoxia | contraindication | 389086002 | |
| Angle-closure glaucoma | contraindication | 392291006 | DOID:13550 |
| Cardiovascular event risk | contraindication | 395112001 | |
| Pseudomembranous enterocolitis | contraindication | 397683000 | |
| Gastric ulcer | contraindication | 397825006 | DOID:10808 |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Chronic lung disease | contraindication | 413839001 | |
| Chronic myocardial ischemia | contraindication | 413844008 | DOID:3393 |
| Disorder of coronary artery | contraindication | 414024009 | |
| Myocardial ischemia | contraindication | 414795007 | DOID:3393 |
| Traumatic injury | contraindication | 417746004 | |
| Central nervous system depression | contraindication | 418072004 | |
| Porphyria | contraindication | 418470004 | |
| Ultrarapid metabolizer due to cytochrome p450 CYP2D6 variant | contraindication | 422681000 | |
| Fever greater than 100.4 Fahrenheit | contraindication | 426000000 | |
| Dysfunction of sphincter of Oddi | contraindication | 430887001 | |
| Hypertensive urgency | contraindication | 443482000 | |
| Smokes tobacco daily | contraindication | 449868002 | |
| Acute exacerbation of asthma | contraindication | 708038006 | |
| Acute Thromboembolic Stroke | contraindication | ||
| Severe Hypoxemia | contraindication | ||
| Theophylline Toxicity | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.22 | Basic |
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 25MG/5ML (5MG/ML) | EPHEDRINE SULFATE | PH HEALTH | N213994 | April 22, 2022 | RX | SOLUTION | INTRAVENOUS | 12029710 | Jan. 22, 2040 | TREATMENT OF CLINICALLY IMPORTANT HYPOTENSION OCCURRING IN THE SETTING OF ANESTHESIA |
| 25MG/5ML (5MG/ML) | EMERPHED | NEXUS | N213407 | Feb. 28, 2023 | RX | SOLUTION | INTRAVENOUS | 11571398 | May 16, 2040 | USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION |
| 50MG/10ML (5MG/ML) | EMERPHED | NEXUS | N213407 | April 17, 2020 | RX | SOLUTION | INTRAVENOUS | 11090278 | May 16, 2040 | USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION |
| 50MG/10ML (5MG/ML) | EMERPHED | NEXUS | N213407 | April 17, 2020 | RX | SOLUTION | INTRAVENOUS | 11241400 | May 16, 2040 | USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION |
| 50MG/10ML (5MG/ML) | EMERPHED | NEXUS | N213407 | April 17, 2020 | RX | SOLUTION | INTRAVENOUS | 11478436 | May 16, 2040 | USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION |
| 50MG/10ML (5MG/ML) | EMERPHED | NEXUS | N213407 | April 17, 2020 | RX | SOLUTION | INTRAVENOUS | 11571398 | May 16, 2040 | USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 25MG/5ML (5MG/ML) | EPHEDRINE SULFATE | FRESENIUS KABI USA | A218271 | March 11, 2025 | RX | SOLUTION | INTRAVENOUS | Feb. 21, 2026 | PATENT CHALLENGE |
| 50MG/10ML (5MG/ML) | EPHEDRINE SULFATE | FRESENIUS KABI USA | A218271 | March 11, 2025 | RX | SOLUTION | INTRAVENOUS | Feb. 21, 2026 | PATENT CHALLENGE |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Beta-2 adrenergic receptor | GPCR | AGONIST | Ki | 5.60 | IUPHAR | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4017462 | VUID |
| N0000179480 | NUI |
| D00124 | KEGG_DRUG |
| 134-72-5 | SECONDARY_CAS_RN |
| 50-98-6 | SECONDARY_CAS_RN |
| 4017462 | VANDF |
| 4018445 | VANDF |
| 4019279 | VANDF |
| C0014479 | UMLSCUI |
| CHEBI:15407 | CHEBI |
| CHEMBL211456 | ChEMBL_ID |
| DB01364 | DRUGBANK_ID |
| CHEMBL1523964 | ChEMBL_ID |
| CHEMBL2146102 | ChEMBL_ID |
| D004809 | MESH_DESCRIPTOR_UI |
| 9294 | PUBCHEM_CID |
| 556 | IUPHAR_LIGAND_ID |
| GN83C131XS | UNII |
| 3966 | RXNORM |
| 3438 | MMSL |
| 4660 | MMSL |
| 4661 | MMSL |
| 6510 | MMSL |
| 71901 | MMSL |
| d00700 | MMSL |
| 001820 | NDDF |
| 001821 | NDDF |
| 001822 | NDDF |
| 387327006 | SNOMEDCT_US |
| 387358007 | SNOMEDCT_US |
| 65026000 | SNOMEDCT_US |
| 76525000 | SNOMEDCT_US |
| GN83C131XS | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Ephedrine Sulfate | HUMAN OTC DRUG LABEL | 1 | 0363-5789 | TABLET, FILM COATED | 25 mg | ORAL | OTC Monograph Drug | 18 sections |
| Ephedrine Hydrochloride | HUMAN OTC DRUG LABEL | 1 | 0363-9812 | TABLET | 12.50 mg | ORAL | OTC Monograph Drug | 18 sections |
| Ephedrine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6236 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 25 sections |
| Ephedrine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0641-6238 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 25 sections |
| Ephedrine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3269 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 24 sections |
| Emerphed | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-250 | INJECTION | 5 mg | INTRAVENOUS | NDA | 25 sections |
| Emerphed-PFS | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-251 | INJECTION | 5 mg | INTRAVENOUS | NDA | 26 sections |
| Emerphed-PFS | HUMAN PRESCRIPTION DRUG LABEL | 1 | 14789-252 | INJECTION | 5 mg | INTRAVENOUS | NDA | 26 sections |
| Ephedrine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16714-037 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 24 sections |
| Ephedrine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-836 | INJECTION, SOLUTION | 50 mg | INTRAVENOUS | ANDA | 25 sections |
| ephedrine sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 36000-336 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 24 sections |
| Ephedrine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-216 | INJECTION, SOLUTION | 50 mg | INTRAVENOUS | NDA | 24 sections |
| Ephedrine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-216 | INJECTION, SOLUTION | 50 mg | INTRAVENOUS | NDA | 24 sections |
| EPHEDRINE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-243 | INJECTION | 5 mg | INTRAVENOUS | NDA | 24 sections |
| EPHEDRINE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-243 | INJECTION | 5 mg | INTRAVENOUS | NDA | 24 sections |
| EPHEDRINE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42023-253 | INJECTION | 5 mg | INTRAVENOUS | NDA | 24 sections |
| Ephedrine sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43598-725 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 24 sections |
| EPHEDRINE SULFATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51662-1325 | INJECTION, SOLUTION | 50 mg | INTRAVENOUS | NDA | 17 sections |
| Akovaz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51754-4200 | INJECTION | 50 mg | INTRAVENOUS | NDA | 24 sections |
| Akovaz | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51754-4250 | INJECTION | 5 mg | INTRAVENOUS | NDA | 24 sections |
| Ephedrine Sulfate | Human Prescription Drug Label | 1 | 55150-373 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 24 sections |
| Ephedrine Sulfate | Human Prescription Drug Label | 1 | 65145-158 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 24 sections |
| Red Label Ephedrine Plus | HUMAN OTC DRUG LABEL | 2 | 65193-125 | TABLET | 12.50 mg | ORAL | OTC monograph final | 9 sections |
| Ephed Plus Liquid | HUMAN OTC DRUG LABEL | 2 | 65193-180 | LIQUID | 25 mg | ORAL | OTC monograph final | 8 sections |
| Ephed Plus | HUMAN OTC DRUG LABEL | 2 | 65193-225 | TABLET | 25 mg | ORAL | OTC monograph final | 9 sections |
| Ephed Asthma | HUMAN OTC DRUG LABEL | 2 | 65193-320 | TABLET | 25 mg | ORAL | OTC monograph final | 9 sections |
| Ephedrine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-257 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 24 sections |
| ephedrine sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-546 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 25 sections |
| ephedrine sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 65219-548 | INJECTION | 5 mg | INTRAVENOUS | ANDA | 25 sections |
| Ephedrine Sulfate | Human Prescription Drug Label | 1 | 68083-495 | INJECTION | 50 mg | INTRAVENOUS | ANDA | 24 sections |